Close Menu

Failure is an Option

Blogger DrugMonkey says that when it comes to NIH grants, a little failure can be a good thing. NIH/CSR review panels seem to be fixated on preliminary data, DrugMonkey says, perhaps because the reviewers think part of their job is to separate the projects that will succeed from those that will fail. But what does it mean to fail?

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.